News & Views

  • CERN Technology Underlies Next Generation Cancer Treatment

CERN Technology Underlies Next Generation Cancer Treatment

Jun 20 2018 Read 408 Times

STFC and Advanced Oncotherapy are collaborating in the construction of a proton therapy assembly and test facility at STFC’s Daresbury Laboratory, that will build on the technology at the heart of the Large Hadron Collider (CERN Geneva)) to develop treatments for patients with cancer.

Proton beams targeted precisely at cancerous tumours will limit damage to surrounding organs or tissue, produce fewer side effects and also offer the potential for higher disease-free survival rates. This therapy is most often used to treat brain tumours in young children whose organs and tissues are still developing, or cancers adjacent to critical part of the body (liver, lung, head and neck, prostate, breast).

Advanced Oncotherapy said that its ‘LIGHT’ system, expected to be the first commercially available linear proton accelerator, would be represent a milestone advancement in cancer therapy, with reduce construction costs and ability to provide hospitals and treatment centres with customisd treatment plans based on a wide range of energies.

UK Science Minister Sam Gyimah said: “Almost all of us have been affected by cancer in some way, whether that’s receiving treatment ourselves or through people we know who have battled the disease. Today’s investment will help develop the next generation of treatments and could take us one step closer to finding a cure, making a huge difference to millions of peoples’ lives.

“The UK remains a leading destination for science, research and innovation and has been home to many of the world’s greatest medical discoveries and development of treatments. Through the Government’s modern Industrial Strategy and Life Sciences Sector Deal, we are encouraging collaboration between industry, academia and business to ensure the UK remains at the forefront of the latest technologies and developments – building a Britain fit for the future.”

Professor Susan Smith, Head of STFC’s Daresbury Laboratory, said the decision was recognition of the Laboratory’s world leading skills and experience in the field of particle accelerators. “At STFC we are committed to developing accelerator technology and expertise to address the world’s key challenges, as well as to help businesses innovate to the benefit of our society and our economy.”

Read comments0

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Digital Edition

International Labmate March 2019

March 2019

In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - Efficient heat transfer - power...

View all digital editions


China Med

Mar 22 2019 Beijing, China


Mar 25 2019 Nantes, France

Bio-Europe Spring

Mar 25 2019 Vienna, Austria

Automaticon 2019

Mar 26 2019 Warsaw, Poland

Forum Labo Paris

Mar 26 2019 Paris, France

View all events